Search Results - "Horn, Candice L."

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies by Zabludoff, Sonya D, Deng, Chun, Grondine, Michael R, Sheehy, Adam M, Ashwell, Susan, Caleb, Benjamin L, Green, Stephen, Haye, Heather R, Horn, Candice L, Janetka, James W, Liu, Dongfang, Mouchet, Elizabeth, Ready, Shannon, Rosenthal, Judith L, Queva, Christophe, Schwartz, Gary K, Taylor, Karen J, Tse, Archie N, Walker, Graeme E, White, Anne M

“…Insights from cell cycle research have led to the hypothesis that tumors may be selectively sensitized to DNA-damaging agents resulting in improved antitumor…”
Get full text

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors by Janetka, James W., Almeida, Lynsie, Ashwell, Susan, Brassil, Patrick J., Daly, Kevin, Deng, Chun, Gero, Thomas, Glynn, Roberta E., Horn, Candice L., Ioannidis, Stephanos, Lyne, Paul, Newcombe, Nicholas J., Oza, Vibha B., Pass, Martin, Springer, Stephanie K., Su, Mei, Toader, Dorin, Vasbinder, Melissa M., Yu, Dingwei, Yu, Yan, Zabludoff, Sonya D.

“…A series of thiophene carboxamide checkpoint kinase inhibitors ( 3) were discovered through HTS and optimized for cellular potency ( 12n). Checkpoint kinase-1…”
Get full text

A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy by Bowers, Rita K, Marder, Philip, Green, Lisa J, Horn, Candice L, Faber, Andrew L, Thomas, James E

“…Thrombin cleavages of selective proteinase-activated receptors (PAR) as well as PAR-activating peptide ligands can initiate the phosphoinositide 3-kinase…”
Get full text

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors by Faivre, Sandrine J., Olszanski, Anthony J., Weigang-Köhler, Karin, Riess, Hanno, Cohen, Roger B., Wang, Xuejing, Myrand, Scott P., Wickremsinhe, Enaksha R., Horn, Candice L., Ouyang, Haojun, Callies, Sophie, Benhadji, Karim A., Raymond, Eric

“…Summary Background This Phase-I-study aimed to determine the recommended Phase-II-dosing-schedule of LY2334737, an oral gemcitabine prodrug, in patients with…”
Get full text

Abstract 29: Concordance of somatic mutations found in primary tumors and plasma circulating-free DNA from early and late-stage colorectal cancer patients by Bray, Steven M., Ebert, Philip J., Calley, John N., Higgs, Richard E., Wulur, Isabella H., Wong, Swee Seong, Horn, Candice L., Martinez, Ricardo, Reinhard, Christoph

“…Abstract Circulating-free DNA (cfDNA) holds great potential for non-invasive somatic mutation detection in cancer patients as a so-called “liquid biopsy”. A…”
Get full text

Abstract 4925: Liquid biopsy using the ion AmpliSeq v2 cancer panel by Liu, WeiHua, Yan, Zhenyu, Horn, Candice L., Nunes, Fabio, Bray, Steven M., Ebert, Philip J., Fang, Peng, Biroschak, Jennifer, Spittle, Cindy, Galderisi, Chad, Li, Jin

“…Abstract Introduction: Plasma cell-free circulating tumor DNA (ctDNA) has the potential to serve as a noninvasive surrogate to determine tumor genotype and…”
Get full text

Abstract LB-048: Copy number and loss of heterozygosity (LOH) analysis in 52 breast cancer FFPE samples using molecular Inversion probe array: detailed analysis of reproducibility and performance compared to NGS platforms by Horn, Candice L., Nunes, Fabio, Calley, John, Bray, Steven, Wulur, Isabella, Farmen, Mark, Gallavan, Robert, Halfpenny, Iris, Medlow, Paul, McGreeghan-Crosby, Keith, Jellema, Gera

“…Abstract Introduction: Somatic mutations are routinely identified using NGS cancer panels but these panels lack genome-wide coverage for copy number (CN) and…”
Get full text